News
Comprehensive coverage on the latest pharmaceutical regulatory update and industry activities in China.
Hot topic
POLICY
[Updated] China's 9th Volume-based Procurement (VBP) Includes 195 Products
On Nov 6, 2023, China announced the preliminary results of the bid for the 9th national volume-based procurement (VBP), a bulk-purchase program for supplying medicines to public healthcare institutions. 266 products (41 drugs if classified by active ingredients) from 205 companies won the bid.
Nov 17, 2023
POLICY
China's 9th Volume-based Procurement (VBP) of Drugs to Impact Market Valued Over USD 2.32 Billion
Out of the 42 drugs to be enrolled in China’s 9th VBP, the top 10 best-selling drugs accounted for approximately USD 2.32 billion in sales in 2022. Two drugs—the immediate-release dosage forms of rabeprazole and propofol injections—each exceeded 3.5 USD billion in last year’s sales.
Oct 20, 2023
REGULATION
Law & Regulation
Guideline
Pharmacopoeia
CMC
Clinical Trial
Volume-based Procurement
Cancer
Drug Registration
Monthly Recap: China Pharmaceutical Regulatory Updates | April 2023
Regulatory updates in Apr. 2023: 1. China Grants Four Rx-to-OTC Switches; China Adjusts Catalogs of Anesthetics and Psychoactive Drugs; China Reveals the 8th Medical VBP’s Bidding Result...
May 15, 2023
POLICY
What's New About China's 8th Volume-based Procurement (VBP) of Drugs
China's 8th medical volume-based procurement (VBP) covers 39 drugs (number based on generic name) with an average price cut of 56%, estimated to save 1.67 million yuan (circa 240,000 USD) annually based on the planned procurement volumes.
Apr 26, 2023
REGULATION
Law & Regulation
Pharmacovigilance
Marketing Approval
Volume-based Procurement
Generic Drug
Drug Registration
E-commerce
2022 Recap: Top 10 BaiPharm Stories on China Pharmaceutical Regulations
ChemLinked BaiPharm Portal has been tracking and interpreting China’s pharmaceutical regulations during the year of 2022. Here are the top 10 stories we selected for you to grasp China’s regulatory dynamics.
Jan 13, 2023
POLICY
China Unveils the Final Drug List for the 7th Volume-based Procurement (VBP)
On July 18, China announced the official list of 327 products for the 7th volume-based procurement (VBP).The 327 products are owned by 217 bid-winning companies, which will supply the products to public health institutions. Among the companies, 6 are international enterprises—Hetero Labs, Bracco Sine, Almirall, Sandoz, and Pfizer.
Jul 25, 2022
POLICY
327 Drug Products to Enter China's 7th Round of Volume-based Procurement (VBP)
Six international pharma companies--Hetero Labs, Bracco Sine, Almirall, Sandoz, Astellas, and Pfizer--won the bid in the preliminary result of the China's 7th round of volume-based procurement (VBP) of drugs.
Jul 15, 2022